Wednesday, July 8, 2026

Patent intelligence · US

US 10844098

Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein

granted A61KA61K2039/575A61K2039/60A61K2039/6087
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 14
Applicant portfolio 335
Patent details — US 10844098

Quick answer

US 10844098 (Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein) is held by Institute of Biotechnology, Academy of Military Medical Sciences, China. Status: granted. Granted Nov 24, 2020. Expires Nov 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61K, A61K2039/575, A61K2039/60, A61K2039/6087, A61K39/0258, A61K39/08

More from Institute of Biotechnology, Academy of Military Medical Sciences, China

Related pharmaceutical patents in our USPTO index.

  1. US 12427137

    Method for reducing methane production in animal stomach

    China Agricultural University · Expires Sep 25, 2045

    granted
  2. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    CGeneTech (Suzhou, China) CO., Ltd. · Expires Sep 18, 2045

    granted
  3. US 12403167

    Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament

    OCEAN UNIVERSITY OF CHINA · Expires Aug 28, 2045

    granted
  4. US 12397034

    Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons

    China Medical University · Expires Aug 21, 2045

    granted
  5. US 12389931

    Oyster peptide with effect of improving sexual function and preparation method thereof

    CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. · Expires Aug 14, 2045

    granted
  6. US 12383535

    Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor

    CHINA PHARMACEUTICAL UNIVERSITY · Expires Aug 7, 2045

    granted
  7. US 12378241

    Pyridine derivative as FGFR and VEGFR dual inhibitors

    CGeneTech (Suzhou, China) CO., Ltd. · Expires Jul 31, 2045

    granted
  8. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 10844098?

US 10844098 (Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein) is held by Institute of Biotechnology, Academy of Military Medical Sciences, China. Status: granted. Granted Nov 24, 2020. Expires Nov 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10844098?

Institute of Biotechnology, Academy of Military Medical Sciences, China is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.

When does US 10844098 expire?

Our index shows an expiration date of Nov 19, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.